Rowlandmiller & PARTNERS.ADV Buys 1,285 Shares of Medtronic PLC $MDT

Rowlandmiller & PARTNERS.ADV increased its holdings in Medtronic PLC (NYSE:MDT) by 8.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,121 shares of the medical technology company’s stock after purchasing an additional 1,285 shares during the quarter. Rowlandmiller & PARTNERS.ADV’s holdings in Medtronic were worth $1,492,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of MDT. Brighton Jones LLC grew its stake in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after purchasing an additional 37,265 shares during the last quarter. Raiffeisen Bank International AG bought a new stake in shares of Medtronic in the fourth quarter worth $756,000. Rafferty Asset Management LLC grew its stake in shares of Medtronic by 11.8% in the fourth quarter. Rafferty Asset Management LLC now owns 145,445 shares of the medical technology company’s stock worth $11,618,000 after purchasing an additional 15,357 shares during the last quarter. Sherbrooke Park Advisers LLC bought a new stake in shares of Medtronic in the fourth quarter worth $1,003,000. Finally, Snowden Capital Advisors LLC grew its stake in shares of Medtronic by 3.3% in the fourth quarter. Snowden Capital Advisors LLC now owns 43,579 shares of the medical technology company’s stock worth $3,512,000 after purchasing an additional 1,374 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president owned 35,615 shares in the company, valued at $3,261,621.70. This represents a 19.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director William R. Jellison bought 2,500 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the acquisition, the director directly owned 5,000 shares in the company, valued at $461,850. The trade was a 100.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.26% of the company’s stock.

Medtronic Price Performance

Shares of NYSE MDT opened at $94.05 on Friday. The firm’s 50-day moving average price is $91.50 and its 200-day moving average price is $88.28. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $96.25. The firm has a market capitalization of $120.64 billion, a P/E ratio of 25.91, a P/E/G ratio of 2.48 and a beta of 0.77. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm had revenue of $8.58 billion for the quarter, compared to analyst estimates of $8.37 billion. During the same quarter in the prior year, the business earned $1.23 earnings per share. The business’s quarterly revenue was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 17th. Investors of record on Friday, September 26th will be issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, September 26th. Medtronic’s dividend payout ratio is currently 78.24%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MDT. Mizuho boosted their price objective on shares of Medtronic from $98.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 16th. Wells Fargo & Company boosted their target price on shares of Medtronic from $98.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, August 20th. Truist Financial boosted their target price on shares of Medtronic from $92.00 to $96.00 and gave the company a “hold” rating in a report on Thursday, August 21st. Royal Bank Of Canada dropped their target price on shares of Medtronic from $105.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, May 22nd. Finally, Leerink Partnrs upgraded shares of Medtronic to a “strong-buy” rating in a report on Monday, June 16th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $102.14.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.